sb 203580 has been researched along with diallyl disulfide in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (diallyl disulfide) | Trials (diallyl disulfide) | Recent Studies (post-2010) (diallyl disulfide) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 474 | 16 | 205 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, J; Lin, M; Ling, H; Su, Q; Tan, H; Yi, L; Zhou, J | 1 |
1 other study(ies) available for sb 203580 and diallyl disulfide
| Article | Year |
|---|---|
Inhibition of ERK and activation of p38 are involved in diallyl disulfide induced apoptosis of leukemia HL-60 cells.
Topics: Allyl Compounds; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Cell Shape; Cell Survival; Disulfides; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Flow Cytometry; HL-60 Cells; Humans; Imidazoles; Leukemia, Promyelocytic, Acute; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Time Factors | 2008 |